The effect of systemic nitric oxide-synthase inhibition on ocular fundus pulsations in man. 1997

L Schmetterer, and K Krejcy, and J Kastner, and M Wolzt, and G Gouya, and O Findl, and F Lexer, and H Breiteneder, and A F Fercher, and H G Eichler
Department of Clinical Pharmacology, University of Vienna, Austria.

There is experimental evidence that endothelium derived nitric oxide is involved in the regulation of ocular vascular tone. The purpose of this study was to investigate the effects of NO-synthase inhibition by N-monomethyl-L-arginine (L-NMMA) on ocular fundus pulsations in young healthy volunteers. Three milligrams per kilograms L-NMMA were administered i.v. over 5 minutes. Protocol 1: Measurements of blood pressure, pulse rate, fundus pulsation amplitude, NO-exhalation, and cardiac output were performed at baseline and 10, 30, 60, 90, 150, and 300 minutes after L-NMMA infusion (n = 8). Fundus pulsation amplitude, which has been shown to estimate the pulsatile component of the choroidal blood flow, was recorded with a recently developed laser interferometer. Protocol 2: Measurements of blood pressure, pulse rate, fundus pulsation amplitude, NO-exhalation, and blood flow velocity in the ophthalmic artery were performed in a randomized, placebo controlled cross over study (n = 10). Ten minutes after L-NMMA administration fundus pulsation amplitude decreased by 23 +/- 2% (protocol 1) and 19 +/- 1% (protocol 2, P < 0.01 each), cardiac output by 12 +/- 2% (P < 0.01), and exhaled NO by 55 +/- 6% (protocol 1) and 41 +/- 6% (protocol 2, P < 0.01 each). All parameters returned to baseline values within the 300 minutes observation period, with a faster recovery of fundus pulsation amplitude than of cardiac output and exhaled NO. Blood pressure, pulse rate, and ophthalmic artery blood flow velocity showed only minor changes during and after administration of L-NMMA. Our results suggest that systemic NO-synthase inhibition reduces pulsatile choroidal and most likely total choroidal blood flow in humans. The recovery of vascular tone in choroidal vessels seems to be different from the cardiovascular response. Our findings indicate that reduced fundus pulsations after L-NMMA are caused by systemic factors as well as by local reactions of the choroidal vasculature.

UI MeSH Term Description Entries
D008297 Male Males
D009569 Nitric Oxide A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of aggregated platelets, and inhibits platelet adhesion to the vascular endothelium. Nitric oxide activates cytosolic GUANYLATE CYCLASE and thus elevates intracellular levels of CYCLIC GMP. Endogenous Nitrate Vasodilator,Mononitrogen Monoxide,Nitric Oxide, Endothelium-Derived,Nitrogen Monoxide,Endothelium-Derived Nitric Oxide,Monoxide, Mononitrogen,Monoxide, Nitrogen,Nitrate Vasodilator, Endogenous,Nitric Oxide, Endothelium Derived,Oxide, Nitric,Vasodilator, Endogenous Nitrate
D009880 Ophthalmic Artery Artery originating from the internal carotid artery and distributing to the eye, orbit and adjacent facial structures. Arteries, Ophthalmic,Artery, Ophthalmic,Ophthalmic Arteries
D011674 Pulse The rhythmical expansion and contraction of an ARTERY produced by waves of pressure caused by the ejection of BLOOD from the left ventricle of the HEART as it contracts. Pulses
D012039 Regional Blood Flow The flow of BLOOD through or around an organ or region of the body. Blood Flow, Regional,Blood Flows, Regional,Flow, Regional Blood,Flows, Regional Blood,Regional Blood Flows
D001783 Blood Flow Velocity A value equal to the total volume flow divided by the cross-sectional area of the vascular bed. Blood Flow Velocities,Flow Velocities, Blood,Flow Velocity, Blood,Velocities, Blood Flow,Velocity, Blood Flow
D002829 Choroid The thin, highly vascular membrane covering most of the posterior of the eye between the RETINA and SCLERA. Choriocapillaris,Haller Layer,Haller's Layer,Sattler Layer,Sattler's Layer,Choroids
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005654 Fundus Oculi The concave interior of the eye, consisting of the retina, the choroid, the sclera, the optic disk, and blood vessels, seen by means of the ophthalmoscope. (Cline et al., Dictionary of Visual Science, 4th ed) Fundus of the Eye,Ocular Fundus,Fundus, Ocular
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

L Schmetterer, and K Krejcy, and J Kastner, and M Wolzt, and G Gouya, and O Findl, and F Lexer, and H Breiteneder, and A F Fercher, and H G Eichler
February 1998, Clinical science (London, England : 1979),
L Schmetterer, and K Krejcy, and J Kastner, and M Wolzt, and G Gouya, and O Findl, and F Lexer, and H Breiteneder, and A F Fercher, and H G Eichler
May 2007, Hypertension research : official journal of the Japanese Society of Hypertension,
L Schmetterer, and K Krejcy, and J Kastner, and M Wolzt, and G Gouya, and O Findl, and F Lexer, and H Breiteneder, and A F Fercher, and H G Eichler
November 2000, Journal of applied physiology (Bethesda, Md. : 1985),
L Schmetterer, and K Krejcy, and J Kastner, and M Wolzt, and G Gouya, and O Findl, and F Lexer, and H Breiteneder, and A F Fercher, and H G Eichler
July 1995, Renal failure,
L Schmetterer, and K Krejcy, and J Kastner, and M Wolzt, and G Gouya, and O Findl, and F Lexer, and H Breiteneder, and A F Fercher, and H G Eichler
January 1995, Biochemical and biophysical research communications,
L Schmetterer, and K Krejcy, and J Kastner, and M Wolzt, and G Gouya, and O Findl, and F Lexer, and H Breiteneder, and A F Fercher, and H G Eichler
September 1998, Current opinion in drug discovery & development,
L Schmetterer, and K Krejcy, and J Kastner, and M Wolzt, and G Gouya, and O Findl, and F Lexer, and H Breiteneder, and A F Fercher, and H G Eichler
January 1997, The British journal of ophthalmology,
L Schmetterer, and K Krejcy, and J Kastner, and M Wolzt, and G Gouya, and O Findl, and F Lexer, and H Breiteneder, and A F Fercher, and H G Eichler
July 1995, The American journal of physiology,
L Schmetterer, and K Krejcy, and J Kastner, and M Wolzt, and G Gouya, and O Findl, and F Lexer, and H Breiteneder, and A F Fercher, and H G Eichler
August 1995, Journal of cardiovascular pharmacology,
L Schmetterer, and K Krejcy, and J Kastner, and M Wolzt, and G Gouya, and O Findl, and F Lexer, and H Breiteneder, and A F Fercher, and H G Eichler
October 1996, Experimental eye research,
Copied contents to your clipboard!